[Laboratory and clinical studies on cefoxitin in the field of obstetrics and gynecology (author's transl)].
1) Serum concentrations of cefoxitin (CFX) was lower than that of cefazolin (CEZ), but the tissue concentrations of CFX were higher in ovary, oviduct and uterus compared with CEZ. 2) CFX was administered to 15 patients with moderate intrapelvic or urinary tract infections at a dose of 4 g per day for 5 to 7 days. The overall results obtained were as follows; excellent in 6 cases, good in 6 cases. The CFX treatment was effective in all patients, 8 cases, with intrapelvic infections. 3) The majority of organisms detected were E. coli (12 strains), and the antimicrobial activity of CFX against them was superior to those of CEZ and CET. 4) No side effects and abnormal laboratory findings were observed. 5) It is considered that CFX will be a useful drug in the field of obstetrics and gynecology.
D000291:Adnexal Diseases / Q000188:drug therapy*; D000328:Adult; D002437:Cefazolin / Q000378:metabolism / Q000627:therapeutic use; D002440:Cefoxitin / Q000378:metabolism / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D004926:Escherichia coli / Q000187:drug effects; D005187:Fallopian Tubes / Q000032:analysis; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000378:metabolism; D008875:Middle Aged; D009215:Myometrium / Q000032:analysis; D010053:Ovary / Q000032:analysis; D014552:Urinary Tract Infections / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000378:metabolism
D002511:Cephalosporins; D002440:Cefoxitin; D002437:Cefazolin